| Name | Section 117: Long-Term Disease Modification Endpoints for CBS/PSP |
| Summary | Comprehensive coverage of disease modification vs symptomatic benefit, delayed-start trial designs, washout paradigms, biomarker endpoints, and regulatory considerations for disease-modifying therapies in corticobasal syndrome and progressive supranuclear palsy |